Clinical and endoscopic features of severe acute gastrointestinal bleeding in elderly patients treated with direct oral anticoagulants: a multicentre study
- PMID: 31244894
- PMCID: PMC6580723
- DOI: 10.1177/1756284819851677
Clinical and endoscopic features of severe acute gastrointestinal bleeding in elderly patients treated with direct oral anticoagulants: a multicentre study
Abstract
Background: The aim of the study was to describe the clinical and endoscopic characteristics and management of severe acute gastrointestinal (GI) bleeding in patients treated with direct oral anticoagulants (DOACs).
Methods: Patients hospitalized for severe GI bleeding under DOAC therapy were identified in 36 centres between June 2013 and March 2016. Clinical outcomes including re-bleeding, major cerebral and cardiovascular events or all-cause mortality were assessed initially and 30 days after admission.
Results: A total of 59 patients with anonymized detailed endoscopy reports for severe GI bleeding were considered. Mean age was 79.3 ± 10.0 years and 61.3% of patients were men. Patients had histories of hypertension (65.6%), heart failure (29.5%), coronary artery disease (27.9%), stroke (19.7%) and peripheral vascular disease (36.1%). Life-threatening bleeding was observed in 42.6%. Mean number of packed red blood cells transfused was 3.4 (range 1-31). Aetiology of bleeding (identified in 66.2% of cases) was peptic gastroduodenal ulcers (22%), diverticula (11.9%), angiodysplasia (8.5%), colorectal neoplasia (5.1%) and anorectal causes (5.1%). Endoscopic haemostasis was performed in 37.7% of patients. A low haemoglobin level was predictive of life-threatening bleeding and death in multivariate analysis. All-cause mortality rate at day 30 was 11.8%.
Conclusions: In this cohort of elderly patients with multiple comorbidities treated with DOACs, the main cause of severe acute GI bleeding was peptic gastroduodenal ulcer and mortality was high.
Keywords: apixaban; dabigatran; direct oral anticoagulants; endoscopy; gastrointestinal bleeding; haemostasis; rivaroxaban.
Conflict of interest statement
Conflict of interest statement: CB has served as a speaker and a consultant for Bayer Healthcare and Boston Scientific. RB has served as a speaker and a consultant for Bayer Healthcare. PA has served as a speaker and a consultant for Aspen Pharmacare, Bayer Healthcare, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Leo Pharma, Novo Nordisk, Pfizer, Portola, Sanofi and Stago. DD, PA and J-MS had no conflict of interest.
Similar articles
-
Severity of Gastrointestinal Bleeding in Patients Treated with Direct-Acting Oral Anticoagulants.Am J Med. 2018 May;131(5):573.e9-573.e15. doi: 10.1016/j.amjmed.2017.11.007. Epub 2017 Nov 22. Am J Med. 2018. PMID: 29175237
-
Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study.Gastroenterology. 2017 Apr;152(5):1014-1022.e1. doi: 10.1053/j.gastro.2016.12.018. Epub 2016 Dec 30. Gastroenterology. 2017. PMID: 28043907
-
A Retrospective Review of Upper Gastrointestinal Bleed Outcomes During Hospital Admission While on Oral Anticoagulation.Cureus. 2021 May 16;13(5):e15061. doi: 10.7759/cureus.15061. Cureus. 2021. PMID: 34150404 Free PMC article.
-
Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban.Clin Res Cardiol. 2013 Jun;102(6):399-412. doi: 10.1007/s00392-013-0560-7. Epub 2013 May 14. Clin Res Cardiol. 2013. PMID: 23669868 Review.
-
Direct oral anticoagulants and digestive bleeding: therapeutic management and preventive measures.Therap Adv Gastroenterol. 2017 Jun;10(6):495-505. doi: 10.1177/1756283X17702092. Epub 2017 Apr 17. Therap Adv Gastroenterol. 2017. PMID: 28567119 Free PMC article. Review.
Cited by
-
Management of blood thinning medications in elderly populations presenting with rectal bleeding: Are we doing right?F1000Res. 2024 Jun 4;13:569. doi: 10.12688/f1000research.149548.1. eCollection 2024. F1000Res. 2024. PMID: 38939367 Free PMC article.
-
Trends in upper gastrointestinal bleeding management.World J Clin Cases. 2024 Sep 26;12(27):6007-6010. doi: 10.12998/wjcc.v12.i27.6007. World J Clin Cases. 2024. PMID: 39328864 Free PMC article.
-
Management dilemmas in restarting anticoagulation after gastrointestinal bleeding.Proc (Bayl Univ Med Cent). 2022 Mar 9;35(3):322-327. doi: 10.1080/08998280.2022.2043707. eCollection 2022. Proc (Bayl Univ Med Cent). 2022. PMID: 35518826 Free PMC article.
-
Impact of clinical characteristics of colonic diverticular bleeding in extremely elderly patients treated with direct oral anti-coagulant drugs: a retrospective multi-center study.J Clin Biochem Nutr. 2021 Sep;69(2):222-228. doi: 10.3164/jcbn.20-140. Epub 2021 Apr 3. J Clin Biochem Nutr. 2021. PMID: 34616113 Free PMC article.
-
Review Article: Gastrointestinal Bleeding Risk with Direct Oral Anticoagulants.Cardiovasc Drugs Ther. 2022 Oct;36(5):973-989. doi: 10.1007/s10557-021-07211-0. Epub 2021 Jun 18. Cardiovasc Drugs Ther. 2022. PMID: 34143317 Review.
References
-
- Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955–962. - PubMed
-
- Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37: 2893–2962. - PubMed
-
- Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Rev Esp Cardiol (Engl Ed) 2018; 71: 110. - PubMed
LinkOut - more resources
Full Text Sources